AstraZeneca Reports 2011 Full-Year and Fourth Quarter Results
AstraZeneca announced its fourth quarter and full-year financial results for 2011. The company faced intensified pricing pressure and generic competition during the period.
Pharmaceutical company AstraZeneca released its fourth quarter and full-year results for 2011 on February 2, 2012. Chief Executive Officer David Brennan stated that the company achieved a good performance in 2011 due to disciplined strategy execution, despite facing increased pricing pressure and competition from generic drugs.
Brennan noted that a strong cash flow supported a significant increase in cash distributions to shareholders, alongside continued investment aimed at future growth and value. However, he cautioned that 2012 was expected to be a challenging year due to further anticipated losses of market exclusivity.
The company reaffirmed its commitment to a long-term, R&D-based strategy. To support this, AstraZeneca announced steps to drive productivity across all areas, with the goal of improving returns on investment in innovation.
The company's announcement also referenced new restructuring initiatives designed to enhance operational efficiency and adapt to the evolving market landscape. The outlook for the coming year was projected to be challenging, primarily due to patent expirations.